Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SNSE | Common Stock | Purchase | $151 | +42 | +0% | $3.60 | 5.23M | Feb 28, 2022 | Direct | F1 |
transaction | SNSE | Common Stock | Purchase | $8.85K | +2.46K | +0.05% | $3.60 | 5.23M | Mar 1, 2022 | Direct | F1 |
Id | Content |
---|---|
F1 | These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. |